Mills EL, Ryan DG, Prag HA, Dikovskaya D, Menon D, Zaslona Z, et al
officinarum , A
Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: pooled analysis of randomized active controlled clinical trials
Elevians CEO, Mark Allen, said the early scientific data on GDF11 is encouraging, but drug discovery and development is a time-intensive, risky, regulated process requiring many years of research, preclinical [animal] studies, and human clinical trials to successfully bring new drugs to market. Flier worries research in the longevity field could be compromised, although he recognizes the importance and promise of the science
It has no known stimulatory effects